Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
The leader of the European Union’s drugs office Guido Rasi said on Monday an underlying authorisation for U.S. pharmaceutical organization Gilead’s remdesivir as a COVID-19 treatment could be conceded in coming days.
The European Medicines Agency (EMA) has just suggested the caring utilization of remdesivir, which permits a medication to be directed to patients even before it has been completely approved.
“It may be that a contingent market authorisation can be given in the coming days,” Rasi told a meeting in the EU Parliament in Brussels.
Aside from remdesivir, Rasi said other potential medications against COVID-19 that might be accessible quick are those dependent on monoclonal antibodies, which can “kill” the new coronavirus (SARS-CoV-2) that causes the ailment COVID-19.